NEW YORK (GenomeWeb) – New data published this month by researchers from Regulus Therapeutics and academic collaborators show that long-term therapeutic silencing of microRNA-33 could result in a number of deleterious effects in mice including fatty liver and elevated triglyceride levels.

Notably, the report comes just months after Regulus and partner AstraZeneca announced they were dropping their miR-33 program in atherosclerosis. At the time, Regulus CSO Neil Gibson said that the decision stemmed from undisclosed challenges facing the effort

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.